William Blair analyst Andrew Brackmann has maintained their bullish stance on VCYT stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Brackmann has given his Buy rating due to a combination of factors that highlight Veracyte’s strong financial performance and promising future prospects. The company’s second-quarter results surpassed expectations, with revenue exceeding consensus estimates and a notable growth in Decipher revenue. Additionally, Veracyte’s AEBITDA margins significantly outperformed expectations, indicating efficient cost management and strategic spending.
Brackmann also points to the company’s upward revision of its 2025 testing revenue guidance, reflecting confidence in sustained growth driven by Decipher and Afirma. Furthermore, Veracyte’s pipeline is poised to unlock additional value with several upcoming catalysts and product launches. The company’s history of successful commercial execution and its current valuation metrics, such as trading at 14 times NTM EBITDA, support the Buy rating as shares are expected to appreciate further.
In another report released today, Needham also reiterated a Buy rating on the stock with a $41.00 price target.